Effects of a novel compound (AL 721) on HTLV-III infectivity in vitro.
P S
PS
Sarin
R C
RC
Gallo
D I
DI
Scheer
F
F
Crews
A S
AS
Lippa
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000368:Aged; D000998:Antiviral Agents / Q000494:pharmacology*; D017977:Deltaretrovirus / Q000187:drug effects* / Q000472:pathogenicity; D004338:Drug Combinations / Q000494:pharmacology; D005989:Glycerides / Q000494:pharmacology*; D006801:Humans; D008214:Lymphocytes / Q000382:microbiology; D010713:Phosphatidylcholines / Q000494:pharmacology*; D010714:Phosphatidylethanolamines / Q000494:pharmacology*; D018894:Reverse Transcriptase Inhibitors
D000998:Antiviral Agents; D004338:Drug Combinations; D005989:Glycerides; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D018894:Reverse Transcriptase Inhibitors; C046637:neutral lipid, phosphatidylcholine, phosphatidylethanolamine drug combination